Literature DB >> 20864054

Management of patients with myoclonus: available therapies and the need for an evidence-based approach.

Joke M Dijk1, Marina A J Tijssen.   

Abstract

Myoclonus is a hyperkinetic movement disorder characterised by quick and involuntary jerks. Therapy should focus on cure of an underlying disorder; however, symptomatic treatment is often needed when treatment of an underlying cause is impossible or ineffective. The appropriate treatment for a specific type of myoclonus is based on the classification of the anatomical origin of the myoclonus: cortical, subcortical, spinal, or peripheral. We outline criteria for classification and present an overview of the available therapeutic options for the different types of myoclonus. Because of a generally low level of evidence, therapeutic options mainly rely on small observational studies and expert opinion. For an evidence-based approach in the future, randomised controlled trials of symptomatic therapies for myoclonus in homogeneous patient groups are needed.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20864054     DOI: 10.1016/S1474-4422(10)70193-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  19 in total

Review 1.  Cardiopulmonary resuscitation and management of cardiac arrest.

Authors:  Jerry P Nolan; Jasmeet Soar; Volker Wenzel; Peter Paal
Journal:  Nat Rev Cardiol       Date:  2012-06-05       Impact factor: 32.419

Review 2.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

3.  Propriospinal myoclonus: is it always psychogenic?

Authors:  Rajesh Verma; Heramba Narayan Praharaj; Tushar Premraj Raut; Dheeraj Rai
Journal:  BMJ Case Rep       Date:  2013-07-29

4.  Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation.

Authors:  Kristoffer Haugarvoll; Charalampos Tzoulis; Gia T Tran; Bjørn Karlsen; Bernt A Engelsen; Per M Knappskog; Laurence A Bindoff
Journal:  J Neurol       Date:  2013-12-03       Impact factor: 4.849

Review 5.  Treatment of myoclonus.

Authors:  John N Caviness
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  The synthetic cannabinoid dehydroxylcannabidiol restores the function of a major GABAA receptor isoform in a cell model of hyperekplexia.

Authors:  Guichang Zou; Jing Xia; Qianqian Han; Dan Liu; Wei Xiong
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

Review 7.  A novel diagnostic approach to patients with myoclonus.

Authors:  Rodi Zutt; Martje E van Egmond; Jan Willem Elting; Peter Jan van Laar; Oebele F Brouwer; Deborah A Sival; Hubertus P Kremer; Tom J de Koning; Marina A Tijssen
Journal:  Nat Rev Neurol       Date:  2015-11-10       Impact factor: 42.937

8.  Sustained Effect of Botulinum Neurotoxin in Myoclonus Owing to Epilepsia Partialis Continua.

Authors:  Janis Rebecca Bedarf; Milena Marek; Christian G Bien; Christian E Elger; Sebastian Paus
Journal:  Mov Disord Clin Pract       Date:  2015-07-15

9.  European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care.

Authors:  Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar
Journal:  Intensive Care Med       Date:  2021-03-25       Impact factor: 17.440

10.  Post-cardiac arrest myoclonus and in ICU mortality: insights from the Parisian Registry of Cardiac Arrest (PROCAT).

Authors:  Omar Ben Hadj Salem; Matthieu Jamme; Marine Paul; Lucie Guillemet; Florence Dumas; Frédéric Pène; Jean-Daniel Chiche; Julien Charpentier; Jean-Paul Mira; Hervé Outin; Eric Azabou; Alain Cariou
Journal:  Neurol Sci       Date:  2021-04-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.